Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?

doi:10.1186/s12985-016-0628-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?

Virology journal - 12 Oct 2016

Mzingwane M L, Tiemessen C T, Richter K L, Mayaphi S H, Hunt G, Bowyer S M

Abstract excerpt

BACKGROUND: Although the use of highly active antiretroviral therapy in HIV positive individuals has proved to be effective in suppressing the virus to below detection limits of commonly used assays, virological failure associated with drug resistance is still a major challenge in some settings. The prevalence and effect of pre-treatment resistance associated variants on virological outcomes may also be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to CD4 Lymphocyte Count
Share to Drug Resistance, Viral
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV-1

Share to HIV Infections

Share to Mutation Rate

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 27733203
DOI: 10.1186/s12985-016-0628-x
PMCID: PMC5062819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.